Tecan Group AG · SIX:TECN
Tecan — FY2015 Earnings Presentation
26 slides from Tecan's earnings presentation, Mar 15, 2016
Slide 1: Full Year Results 2015
Zurich, March 15 2016 Full Year Results 2015 ANALYST & MEDIA CONFERENCE
Slide 2: Speakers
Speakers Dr. David Martyr, CEO Dr. Rudolf Eugster, CFO 2
Slide 3: Agenda
Agenda INTRODUCTION FINANCIAL RESULTS PRIORITIES OUTLOOK QUESTIONS AND ANSWERS 3
Slide 4: Financial Performance 2015
Financial Performance 2015 • Strong financial performance, delivering on commitments for the year • Both business segments growing with double-digit rate in local currencies • Recurring revenues increased to 38% of total sales, including strong performance from IBL International immunoassays • Opera
Slide 5: Operating Highlights 2015
Operating Highlights 2015 • Launch of the 2nd and 3rd wave of innovation for the Fluent™ laboratory automation family, Tecan’s next generation liquid handling platform • Launch of all-new multimode reader platform Spark™ 10M, conclusion of development of Spark™ 20M, the most productive reader with i
Slide 6: Agenda
Agenda INTRODUCTION FINANCIAL RESULTS PRIORITIES OUTLOOK QUESTIONS AND ANSWERS 6
Slide 7: 2015 Order Entry and Sales Performance
2015 Order Entry and Sales Performance ORDER ENTRY FY 2015 ORDER ENTRY H2 2015 VS. H2 2014 465.0 470 • +10.9% in Swiss Francs 450 • +13.8% in local currencies • Organic +12.3% in local currencies CHF (mio) 430 417.4 410 ORDER ENTRY FY 2015 VS. FY 2014 390 • +11.4% in Swiss Francs 370 • +14.1% in loc
Slide 8: 2015 Segment Sales
2015 Segment Sales SALES (IN CHF MILLIONS) LIFE SCIENCES BUSINESS: 260.0 253.0 2014 H2 • Sales up by 7.5% in CHF and 12.7% higher in 240.0 236.3 local currencies (LC) 2015 220.0 • Organic sales growth of +11.3% in LC 200.0 187.3 FY • Sales 7.1% above prior-year in CHF and 11.8% 180.0 higher in LC 16
Slide 9: FY 2015 Regional Sales Development
FY 2015 Regional Sales Development YoY % YoY % +12.3% in LC -10.1% in LC EUROPE: +3.6% in CHF -19.6% in CHF • Life Sciences Business growth driven by newly Others launched products and IBL International reagents 2% • Partnering Business with solid sales for instruments and components Asia NORTH AMER
Slide 10: FY 2015 Gross Profit
FY 2015 Gross Profit GROSS PROFIT (% = % OF SALES) 220 215.5 GROSS PROFIT INCREASED TO CHF 215.5M 210 • CHF 17.9m or 9.0% above 2014 200 197.6 CHF (mio) GROSS PROFIT MARGIN DOWN BY 60 BPS 190 • (-) Product mix impact: higher sales contribution from new products with lower profitability in the 49.5%
Slide 11: FY 2015 Cost Structure
FY 2015 Cost Structure OPERATING EXPENSES (% = % OF SALES) OPERATING EXPENSES GREW LESS THAN SALES 160 150.0m 142.5m (34.1%) (35.6%) 140 • OPEX expansion of 5.3% compared to sales growth of 10.2% 120 69.2 63.3 (15.7%) 100 (15.8%) • All operating expenses include costs from CHF (mio) acquired busines
Slide 12: FY 2015 EBIT and EBITDA
FY 2015 EBIT and EBITDA EBIT AND EBITDA (IN CHF MILLIONS) EBIT INCREASED TO CHF 66.9M 85 83.4 • CHF 9.7m or 17.0% above 2014 EBIT 75 EBITDA 67.5 66.9 EBIT MARGIN AT 15.2% 65 Main effects impacting the EBIT margin: 57.2 • (-) GP margin 60 bps lower 55 • (+) Expenses 150 bps lower 45 2014 2015 EBIT AN
Slide 13: FY 2015 Segment Profitability
FY 2015 Segment Profitability EBIT (IN CHF MILLIONS) 50 45.4 LIFE SCIENCES BUSINESS: 40.2 40 • EBIT margin increased to 17.0% 30.2 • (+) Positive price effect 30 24.9 2014 • (+) Positive volume effect 2015 20 • (+) Reduced R&D expenses 10 0 PARTNERING BUSINESS: Life Sciences Partnering Business Busi
Slide 14: FY 2015 Net Profit
FY 2015 Net Profit NET PROFIT (% = % OF SALES) NET PROFIT GREW FASTER THAN SALES • CHF 16.9m or 42.1% higher than 2014 60 57.1 EBIT INCREASE OF CHF 9.7M 50 40.2 BELOW EBIT LINE 40 • (+) Improved financial result CHF (mio) • (+) Lower tax rate of 13.4% (2014: 18.2%) 30 48.8% 49.5% NET PROFIT MARGIN +
Slide 15: FY 2015 Basic Earnings per Share
FY 2015 Basic Earnings per Share BASIC EARNINGS PER SHARE 5.50 5.05 5.00 EARNINGS PER SHARE INCREASED BY 4.50 39.1% TO CHF 5.05 4.00 3.63 AVERAGE NUMBER OF SHARES CHF / share 3.50 3.00 OUTSTANDING: 11.3M (2014: 11.1M) 48.8% 49.5% 2.50 INCREASE IN DIVIDEND FROM CHF 1.50 TO 48.8% 49.5% 2.00 CHF 1.75 T
Slide 16: FY 2015 Cash Flow
FY 2015 Cash Flow +99.1 +14.1 208.4 -14.6 -18.9 128.7 Cash at end of From Operations From Investments From Financing1 Investment Cash at end 2014 SIAS of 2015 CASH FLOW FROM OPERATIONS MORE THAN DOUBLED TO CHF 99.1M (2014: CHF 48.2M) • High cash conversion of 22.5% of sales; operating cash flow sign
Slide 17: FY 2015 Key Figures
FY 2015 Key Figures 2014 2015 Δ IN % Sales (in CHF mio) 399.5 440.3 +10.2% Sales in local currencies (in CHF mio) 389.2 440.3 +13.1% Gross Profit (in CHF mio) 197.6 215.5 +9.0% in % of sales 49.5% 48.9% R&D (in CHF mio) 39.5 39.9 +1.0% in % of sales 9.9% 9.1% EBIT (in CHF mio) 57.2 66.9 +17.0% in %
Slide 18: Agenda
Agenda INTRODUCTION FINANCIAL RESULTS PRIORITIES OUTLOOK QUESTIONS AND ANSWERS 18
Slide 19: Review of Priorities of 2015
Review of Priorities of 2015 • 2nd and 3rd wave launches for Fluent Driving growth in Life Sciences Business: • Launched all-new reader platform Spark focus on launch of new products, continued • Further growth with IBL immunoassays IBL integration and China expansion • Solid growth in China, overal
Slide 20: Priorities for 2016
Priorities for 2016 • Material cost savings • Supply chain management Operational efficiency • Productivity projects • Maintaining fast pace of innovation • New product launches • Delivery ramp-up Partnering Business • Concluding new development agreements • Sias integration • Growth from new instru
Slide 21: Agenda
Agenda INTRODUCTION FINANCIAL RESULTS PRIORITIES OUTLOOK QUESTIONS AND ANSWERS 21
Slide 22: Outlook for 2016
Outlook for 2016 SALES Double-digit sales growth in local currencies PROFITABILITY EBITDA (in CHF mio) at about similar level as 2015 • Including integration costs in a mid single-digit million CHF amount related to the Sias acquisition (accretive in 2017) Underlying EBITDA margin to expand by at le
Slide 23: Upcoming Event
Upcoming Event - Savethe date — _ _ Capital Markets oe J b= Day 2016
Slide 24: Q&A
Q&A IR IPAD APP News, financial reports, presentations, videos and more NEXT EVENTS 2016: April 13: Annual Shareholder Meeting June 16: Capital Markets Day August 16: Half Year Results 2016 CONTACT Martin Braendle Vice President, Communications & IR Phone: +41 (0) 44 922 84 30 investor@tecan.com www
Slide 25: Tecan – Who we are
Tecan – Who we are Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the lif
Slide 26: 26
26